• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

CardioKinetix

edit

The Company, based in Menlo Park, has developed a novel transcatheter implant called the PARACHUTETM Ventricular Partitioning Device (PARACHUTETM). The PARACHUTETM intends to treat heart failure resulting from a heart attack or myocardial infarction in millions of patients worldwide by improving overall cardiac function.

Recent Milestones

edit

• 
  CardioKinetix received $4M in Series E funding. (2/28/13)
  Posted 2/28/13 at 9:25pm via dowjones.com
• 
  CardioKinetix received $44M in Series E funding. (9/21/11)
  Posted 9/21/11 at 10:23pm via finsmes.com
• 
  CardioKinetix added Wes Johnson as President, CEO and Director.
  Posted 9/21/11 at 10:23pm
• 
  CardioKinetix added Serjan D. Nikolic as CTO and Director.
  Posted 9/21/11 at 10:23pm
• 
  CardioKinetix added Maria Sainz as President, CEO and Director.
  Posted 5/7/12 at 7:57pm

Videos

Screenshots

edit

Sources

1. CardioKinetix Raises $44M in Series E Financing (finsmes.com) [edit]
2. CardioKinetix Adds $4M to $44M Series E for Heart Implant (pevc.dowjones.com) [edit]